Title:The Glioblastoma Problem: Targeting by Combined Medicinal Chemistry Approaches
Volume: 22
Issue: 21
Author(s): Guido Frosina
Affiliation:
关键词:
共济失调毛细管扩张突变，联合治疗，诊断，胶质瘤初始细胞，胶质瘤，抑制剂，MYC，预后，治疗
摘要: Whilst knowledge of basic biology, diagnosis and prognosis of glioblastoma (GB – WHO
grade IV) are steadily improving, advancements of therapy are discouragingly slow, with the only significant
novelty during last ten years represented by introduction of temozolomide in chemotherapy. In
order to analyze the current status of clinical research on GB, a literature search was conducted in
PubMed using the terms: “glioma AND trial” over a 500 day period elapsing from Jan 1, 2013 to May
15, 2014 and results of Phase I, II and III trials were reviewed. Results in the pediatric setting were included
as well. It was concluded that, as in other cancer research areas, an overwhelming amount of
pre-clinical research acquisitions in the GB field are not presently translated to improved patients’ survival. In order to
explore novel therapeutic avenues for this deadly tumour, two innovative medicinal chemistry approaches are proposed
and discussed: a) Specific glioma initiating cell-radiosensitization by ATM inhibitors [1] and b) Specific glioma initiating
cell-chemotherapeutic targeting by MYC inhibitors [2].
